Treats Attention Deficit Hyperactivity Disorders (ADHD) and Narcolepsy. ANDA 40300, held by SpecGx. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 40300 (Methylphenidate Hydrochloride), held by SpecGx, was first approved by FDA on Nov 27, 1998, with 8 approved supplements and 0 published complete response letters.
Methylphenidate hydrochloride tablets are indicated for the treatment of: Attention Deficit Hyperactivity Disorders (ADHD) in pediatric patients 6 years and older and adults Narcolepsy Methylphenidate hydrochloride is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorders (ADHD) and Narcolepsy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 27, 1998 | Original application | Approved |
| Methylphenidate Hydrochloride5MG · tablet;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride10MG · tablet;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride20MG · tablet;oral | Methylphenidate Hydrochloride | Rx |
| Oct 28, 2016 | Supplement 17Labeling · Standard review | Approved | None posted |
| Oct 28, 2016 | Supplement 18Labeling · Standard review | Approved | None posted |
| Mar 20, 2015 | Supplement 15Labeling · Standard review | Approved | None posted |
| Jan 21, 2014 | Supplement 13Labeling · Standard review | Approved | None posted |
| Dec 19, 2012 | Supplement 11Labeling | Approved | None posted |
| Dec 10, 2010 | Supplement 7Labeling | Approved | None posted |
| Mar 2, 2006 | Supplement 6Labeling | Approved | None posted |
| Apr 24, 2003 | Supplement 1Labeling | Approved | None posted |
| Nov 27, 1998 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters